REG - IXICO plc - Contract win and contract extension

IXICOAnnouncement

21/05/2026 07:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20260521:nRSU1444Fa&default-theme=true

RNS Number : 1444F  IXICO plc  21 May 2026

IXICO plc

("IXICO", the "Company" or the "Group")

 

Alzheimer's contract win and Phase 2 clinical trial contract extension with
total value of £1.3 million

 

 

21 May 2026, IXICO plc (AIM: IXI) - London, UK. IXICO, a global leader in
neuroscience imaging and biomarker analytics, using its AI-driven platform to
help advance drug and diagnostics development in neurological disorders, today
announced a contract win and contract extension with a total value of £1.3
million over 2 years.

 

Blood based biomarker validation contract

IXICO will provide amyloid PET imaging analytics to validate a new Alzheimer's
Disease (AD) blood-based biomarker test for a global diagnostics and life
sciences company with the aim of facilitating FDA regulatory clearance.

 

Phase 2 contract extension

This extends an existing Phase 2 Huntington's Disease (HD) clinical trial
contract with a leading global pharmaceutical company, expanding the existing
analysis methodologies with three additional analysis approaches.

 

Bram Goorden, Chief Executive Officer of IXICO, commented: "These latest
contract wins are first and foremost important for progress in research and
patient care. They also fit squarely in the growth strategy for our company,
hitting three key components of the plan: deepening impact in broader CNS
areas such as AD while maintaining leadership in rare neurodegenerative
disease areas like HD, enabling novel modalities and moving toward high-value
later stage clinical development work. It is deeply satisfying to see an
increasing number of clients recognise IXICO's leading role in the field of
CNS precision medicine".

 

The information contained within this announcement is deemed by the Company to
constitute inside information as stipulated under the UK version of the EU
Market Abuse Regulation 596/2014 which is part of UK law by virtue of the
European Union (Withdrawal) Act 2018, as amended and supplemented from time to
time. Upon the publication of this announcement, this inside information is
now considered to be in the public domain.

 

Ends

 

For further information please contact:

 

 IXICO plc                                        +44 (0) 20 3763 7499
 Grant Nash, Chief Financial Officer

 James Chandler, Chief Business Officer

 Cavendish Capital Markets Limited                +44 (0) 20 7220 0500

 (Nominated Adviser and Sole Broker)
 Giles Balleny, Isaac Hooper (Corporate Finance)

 Nigel Birks (Healthcare Specialist Sales)

 Harriet Ward (Corporate Broking)

 Michael F Johnson (Sales)

 

 

About IXICO www.IXICO.com (http://www.IXICO.com)

IXICO is a global leader in neuroscience imaging and biomarker analytics,
using its proprietary AI-driven platform to help advance the treatment of
neurological disorders and reduce the uncertainties associated with drug
discovery, development and monitoring.   As a key part of the global
neurological disease research community, the Company has built a global
reputation and 20-year track record as an end-to-end Imaging Contract Research
Organisation (iCRO) working with leading pharma companies, innovative
biotech's, disease consortia and non-profit organisations. IXICO has supported
hundreds of neurological clinical trials, analysed hundreds of thousands scans
and built an expansive network of expert imaging centres around the world.

 

The IXICO Platform is tailor-made for neurological disease, reliably
processing data from global trials, precisely measuring key imaging biomarkers
associated with the identification, progression and treatment of diseases such
as Alzheimer's, Huntington's and Parkinson's.  Image data is interrogated by
the Platform and IXICO's expert scientists translating complex data into
clinically meaningful while minimizing data variability and increasing
reproducibility.

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  CNTXBLFLQELZBBZ



            Copyright 2019 Regulatory News Service, all rights reserved